Overview

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.

Phase:

Phase 2

Details

Lead Sponsor:

Argos Therapeutics

Treatments:

Sunitinib